GlassScriptPhysician profile
Andres Palomo
NPI 1295730422
$7,346.18
in general payments reported to CMS, 2019-2025
23 companies · $3,557 in 2025
The $3,557 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $473 · 2020: $126 · 2021: $613 · 2022: $445 · 2023: $717 · 2024: $1,414 · 2025: $3,557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,081 · Travel and Lodging: $608.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,081.14 |
| Travel and Lodging | $607.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $1,629.73 | 2023-2025 | Evoque, Pascal, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Boston Scientific Corporation | $1,490.23 | 2023-2025 | Watchman Flx, General - Therapies, Varithena Administration Pack |
| Biotronik INC. | $938.78 | 2019-2022 | |
| Abbott Laboratories | $632.70 | 2024-2025 | Aveir, Portico, Gallant |
| Cardiva Medical, INC. | $592.59 | 2022-2025 | Cardiva Vascade 6/7f Vcs, Cardiva Vascade Mvp Vvcs 6-12f |
| Recor Medical INC | $329.43 | 2025 | Paradise Ultrasound Renal Denervation System |
| Shockwave Medical, INC | $267.77 | 2019-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Medtronic, INC. | $264.36 | 2023-2025 | Symplicity G3, Azure Xt Dr Mri Surescan |
| Biosense Webster, INC. | $257.81 | 2024-2025 | Na, Carto 3 |
| Atricure, INC. | $177.77 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $170.35 | 2019-2025 | Camzyos |
| Heartflow, INC. | $148.70 | 2025 | |
| Abiomed | $110.29 | 2025 | |
| Janssen Pharmaceuticals, INC | $78.00 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $46.59 | 2024-2025 | Wainua, Farxiga |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $45.13 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $34.90 | 2022-2024 | Verquvo |
| Alnylam Pharmaceuticals INC. | $31.59 | 2025 | Amvuttra |
| Glaxosmithkline, LLC. | $27.29 | 2025 | Shingrix, Arexvy |
| Vital Connect, INC | $25.21 | 2025 | Vitalpatch Rtm |
| Sanofi-Aventis U.S. LLC | $18.61 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.47 | 2021 | |
| Lilly USA, LLC | $12.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andres Palomo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.